SCHEMBL5469616

SCHEMBL5469616

Cc1cc(C(=O)OCc2ccccc2)[nH]c1C=C1C(=O)Nc2ccccc21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.81
FGFR1 P11362 7/20 0.58
PDGFRB P09619 6/20 0.58
RET P07949 5/20 0.58
FLT3 P36888 5/20 0.58
FLT1 P17948 5/20 0.58
ALK Q9UM73 4/20 0.58
CSF1R P07333 3/20 0.58
SRC P12931 3/20 0.58
FGFR3 P22607 3/20 0.58
FLT4 P35916 3/20 0.58
AURKA O14965 3/20 0.58
MAP4K2 Q12851 3/20 0.58
STK3 Q13188 3/20 0.58
AURKB Q96GD4 3/20 0.58
PDPK1 O15530 3/20 0.58
ZAP70 P43403 3/20 0.58
MAPK1 P28482 2/20 0.58
ABL1 P00519 2/20 0.58
PLK4 O00444 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469611 1.00 KDR (0.81) KDRFGFR1PDGFRBRETFLT3
SCHEMBL5480551 0.92 KDR (0.75) KDRFGFR1PDGFRBRETFLT3
SCHEMBL5480552 0.92 KDR (0.75) KDRFGFR1PDGFRBRETFLT3
SCHEMBL5465247 0.89 KDR (1.00) KDRFGFR1PDGFRBRETFLT3
SCHEMBL5465253 0.89 KDR (1.00) KDRFGFR1PDGFRBRETFLT3
SCHEMBL2117299 0.85 KDR (0.80) KDRFGFR1PDGFRBRETFLT3
SCHEMBL2117305 0.85 KDR (0.80) KDRFGFR1PDGFRBRETFLT3
SCHEMBL2114209 0.84 KDR (0.73) KDRFGFR1PDGFRBRETFLT3
SCHEMBL2114210 0.84 KDR (0.73) KDRFGFR1PDGFRBRETFLT3
SCHEMBL31672504 0.84 KDR (0.73) KDRFGFR1PDGFRBRETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 KDR 4334/4885FGFR1 4752/4885PDGFRB 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.